Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma DOI Creative Commons
Matteo Villa, Geeta G. Sharma, Federica Malighetti

et al.

British Journal of Cancer, Journal Year: 2024, Volume and Issue: 131(11), P. 1781 - 1795

Published: Oct. 30, 2024

Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive T-cell lymphoma, classified into ALK-positive ALK-negative subtypes, based on the presence of chromosomal translocations involving ALK gene. The current standard treatment for ALCL polychemotherapy, with high overall survival rate. However, subset patients does not respond to or develops resistance these therapies, posing serious challenge clinicians. Recent targeted treatments such as kinase inhibitors anti-CD30 antibody-drug conjugates have shown promise but, fraction patients, prognosis still unsatisfactory.

Language: Английский

Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies DOI

Jiawei Song,

Jun Zhu,

Yu Jiang

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: 1880(2), P. 189277 - 189277

Published: Feb. 10, 2025

Language: Английский

Citations

2
The Function of Circular RNAs in Regulating Wnt/β-Catenin Signaling: An Innovative Therapeutic Strategy for breast and gynecological Cancers DOI

Samaneh Kahkesh,

Neda Hedayati,

Payman Rahimzadeh

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155944 - 155944

Published: March 1, 2025

Language: Английский

Citations

1
Mechanisms of the JNK/p38 MAPK signaling pathway in drug resistance in ovarian cancer DOI Creative Commons
Yuting Ma, Chan Li, Ying Shen

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: April 24, 2025

Ovarian cancer (OC) is the most lethal malignancy in female reproductive system, and chemotherapy drug resistance main cause of treatment failure. The Mitogen-Activated Protein Kinases (MAPK) pathway plays a pivotal role regulating cell proliferation, migration, invasive capacity response to extracellular stimuli. This review focuses on mechanisms therapeutic strategies related JNK/p38 MAPK signaling OC resistance. dual chemoresistance. examines its mediating by exploring action pathway, particularly involvement several key biological processes, including apoptosis, autophagy, DNA damage response, tumor microenvironment (TME), efflux. Additionally, investigates timing activation this crosstalk with other pathways such as PI3K/AKT NF-κB. Targeting has shown promise reversing chemoresistance, inhibitors natural compounds demonstrating potential preclinical studies. Regulating may transform what was once terminal obstacle into manageable challenge for patients resistance, ultimately improving survival quality life.

Language: Английский

Citations

0
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma DOI Creative Commons
Matteo Villa, Geeta G. Sharma, Federica Malighetti

et al.

British Journal of Cancer, Journal Year: 2024, Volume and Issue: 131(11), P. 1781 - 1795

Published: Oct. 30, 2024

Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive T-cell lymphoma, classified into ALK-positive ALK-negative subtypes, based on the presence of chromosomal translocations involving ALK gene. The current standard treatment for ALCL polychemotherapy, with high overall survival rate. However, subset patients does not respond to or develops resistance these therapies, posing serious challenge clinicians. Recent targeted treatments such as kinase inhibitors anti-CD30 antibody-drug conjugates have shown promise but, fraction patients, prognosis still unsatisfactory.

Language: Английский

Citations

0